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Abstract
Introduction: Patients with neurogenic bladder due to spina bifida are considered to be at
increased risk for aggressive bladder cancer. We present a unique case of a 32-year-old woman
with spina bifida diagnosed with sarcomatoid urothelial carcinoma of the bladder and report
diagnosis and management.
Case presentation: A 32 year old woman with neurogenic bladder managed with intermittent
self catheterisations, presented with gross hematuria. On cystoscopy, she had a bulky bladder mass
on the posterior bladder wall. Bladder biopsies revealed sarcomatoid variant of bladder transitional
cell carcinoma. Treatment included radical cystectomy with ileal conduit diversion and adjuvant
chemotherapy with excellent intermediate term follow up.
Conclusion: Patents with neurogenic bladder managed with intermittent self catheterisations
need periodical follow up due to increased risk for aggressive bladder cancer. Immediate radical
cystectomy with adjuvant chemotherapy is the suggested treatment approach.
Introduction
Patients with neurogenic bladder due to spina bifida (SB)
are considered to be at increased risk for bladder cancer.
These tumours are composed of urothelial, glandular or
small cell component showing variable degrees of differ-
entiation, while a small subset may have a prominent
myxoid stroma [1]. We report a case of bladder cancer of
the sarcomatoid variant in a young woman with neuro-
genic bladder due to SB, and we present the diagnostic
evaluation, management and intermediate-term out-
come.
Case presentation
A 32-year-old Greek white woman with neurogenic blad-
der due to spina bifida managed with intermittent self
catheterizations since puberty; presented with gross
hematuria and recurrent urinary tract infections. There
was no history of bladder cancer in patient's family. Cys-
toscopy showed a bulky solid mass occupying the poste-
rior bladder wall. Computed tomography didn't show
nodal or distant metastases. Bladder biopsies revealed
muscle-invasive sarcomatoid urothelial carcinoma with
carcinoma in situ of the bladder neck. Radical cystectomy
with anterior pelvic exenteration and ileal conduit forma-
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tion was performed. Microscopically, the tumor was a
high-grade urothelial carcinoma, Grade III according to
the classification of the World Health Organization
(WHO) of 1973, invading the whole bladder-wall and the
pericystic lipoid tissue (stage pT3a). A large subset of the
tumor assumed a spindle cell/sarcomatoid appearance
with high mitotic rate and atypical mitoses. Immunohis-
tochemically, the tumor cells were positive for the epithe-
lial membrane antigen (EMA), cytokeratin 18 (CK18) and
Vimentin. Some tumor cells were positive for CD117 (c-
kit), whereas all of them were negative for CK7, CK20,
Desmin and CD34 (Figure 1, and Figure 2). These histo-
logic and immunohistochemical evidence of both epithe-
lial and mesenchymal differentiation classify this tumor,
as sarcomatoid variant of urothelial carcinoma without
heterologous elements. The patient has completed 4
cycles of gemcitabine and carboplatine and at 9 months of
follow-up remains disease free
Discussion
Patients with neurogenic bladder are considered to be at
high risk for bladder malignancies, with the vast majority
of data coming from series of spinal cord injured patients
[2]. Less than 20 cases of patients with spina bifida (SB)
and urothelial bladder cancer have been reported in the
literature, mainly presenting with locally advanced or
metastatic disease [3]. Patients present with nonspecific
symptoms, since gross hematuria was the main symptom
in only 63% of cases. The median survival was only 6
months [4].
This is the first report of bladder urothelial carcinoma of
the sarcomatoid variant diagnosed in a young patient
with spina bifida.
Recent molecular studies support a monoclonal cell ori-
gin and suggest that clonal divergence may occur during
tumor progression and differentiation [5].
Sarcomatoid carcinoma is a biphasic malignant neoplasm
exhibiting morphologic and/or immunohistochemical
evidence of epithelial and mesenchymal differentiation
By immunohistochemistry, epithelial elements react with
cytokeratins, whereas stromal elements react with Vimen-
tin or specific markers corresponding to the mesenchymal
differentiation. Microscopically, it is composed of spindle
cell/sarcomatoid elements with high mitotic rate and
atypical mitoses [6].
In conclusion, high index of clinical suspicion and appro-
priate usage of immunohistochemical techniques are
essential for fast diagnosis of this rare clinical entity. Pri-
mary radical cystectomy and adjuvant chemotherapy may
improve outcomes.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MN operated on the patient, analysed and interpreted the
data and revised the manuscript PF was a major contribu-
tor to the writing of the case report and completed the lit-
erature search CG performed the histological examination
Hematoxylin-eosin × 400 showing high frade urothelial carci- noma of the bladder Figure 1
Hematoxylin-eosin × 400 showing high frade urothe-
lial carcinoma of the bladder.
Cytokeratin 18 immunostaining ×200: positive for malignant  spindle cell tumor in the urinary bladder Figure 2
Cytokeratin 18 immunostaining ×200: positive for 
malignant spindle cell tumor in the urinary bladder.Publish with BioMed Central    and   every 
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